Pathophysiologic mechanisms of calcific aortic stenosis

Therapeutic Advances in Cardiovascular Disease

Volumn 6, Issue 2, 2012, Pages 71-80

  Alexopoulos, Alexandros ^a   Kaoukis, Andreas ^b   Pyrgakis, Vlassios ^b   Papadaki, Helen ^c  

^a IASO GENERAL HOSPITAL   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

aortic; calcific; pathophysiologic; stenosis

Indexed keywords

ALKALINE PHOSPHATASE; APOLIPOPROTEIN E; BONE MORPHOGENETIC PROTEIN; CATHEPSIN G; CD31 ANTIGEN; CD34 ANTIGEN; CYSTATIN C; GLYCOPROTEIN; HEAT SHOCK PROTEIN 60; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MACROPHAGE ELASTASE; OSTEOCLAST DIFFERENTIATION FACTOR; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR; VON WILLEBRAND FACTOR;

AGE; ANATOMY; AORTA STENOSIS; CALCIFIC AORTIC STENOSIS; CALCIUM METABOLISM; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DISEASE COURSE; ENDOTHELIUM; ENZYME ACTIVITY; GENETIC VARIABILITY; HEART MUSCLE CELL; HISTOLOGY; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DYSFUNCTION; LIPOPROTEIN BLOOD LEVEL; MECHANICAL STRESS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SEX; SHORT STATURE; SMOKING; T LYMPHOCYTE ACTIVATION; UPREGULATION; VALVULAR INTERSTITIAL CELL;

ANIMALS; AORTIC VALVE STENOSIS; ATHEROSCLEROSIS; CALCINOSIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INFLAMMATION; OSTEOGENESIS;

EID: 84860804250     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944712439337     Document Type: Review

References (50)

1. Aikawa E. Aikawa M. Libby P. Figueiredo J. Rusanescu G. Iwamoto Y. et al. (2009) Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 119: 1785–1794.
2. Alexopoulos A. Bravou V. Peroukides S. Kaklamanis L. Varakis J. Alexopoulos D. et al. (2010) Bone regulatory factors NFATc 1 and Osterix in human calcific aortic valves. Int J Cardiol 139: 142–149.
3. Alexopoulos A. Michelakakis N. Papadaki H. (2011 a) Pathophysiologic mechanisms of age-related aortic valve calcification. In Ed. Masanori H. (ed.), Aortic Stenosis: etiology, Pathophysiology and Treatment. Intechweb.
4. Alexopoulos A. Peroukides S. Bravou V. Varakis J. Pyrgakis V. Papadaki H. (2011 b) Implication of bone regulatory factors in human coronary artery calcification. Artery Res 5: 101–108.
5. Anger T. Carson W. Weyand M. Daniel W.G. Hoeher M. Garlichs C.D. (2009) Atherosclerotic inflammation triggers osteogenic bone transformation in calcified and stenotic human aortic valves: still a matter of debate. Exp Mol Pathol 86: 10–17.
6. Arishiro K. Hoshiga M. Negoro N. Jin D. Takai S. Miyazaki M. et al. (2007) Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 49: 1482–1489.
7. Boss Y. Mathieu P. Pibarot P. (2008) Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis. J Am Coll Cardiol 51: 1327–1336.
8. Bratos-Perez M.A. Sanchez P.L. Garcia de Cruz S. Villacorta E. Palacios I.F. Fernandez-Fernandez J.M. et al. (2008) Association between self-replicating calcifying nanoparticles and aortic stenosis: a possible link to valve calcification. Eur Heart J 29: 371–376.
9. Caira F.C. Stock S.R. Gleason T.G. McGee E.C. Huang J. Bonow R.O. et al. (2006) Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006.2002.2040v2001: 1707–1712.
10. Freeman R. Otto C. (2010) Aortic valve disease. In Ed. Fuster V. Walsh R. Harrington R. (eds), Hurst's the Heart (13th ed.). New York: McGraw-Hill.
11. Garg V. Muth A.N. Ransom J.F. Schluterman M.K. Barnes R. King I.N. et al. (2005) Mutations in NOTCH 1 cause aortic valve disease. Nature 437: 270–274.
12. Hakuno D. Kimura N. Yoshioka M. Mukai M. Kimura T. Okada Y. et al. (2010) Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J Clin Invest 120: 2292–2306.
13. Helske S. Syvaranta S. Kupari M. Lappalainen J. Laine M. Lommi J. et al. (2006 a) Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J 27: 1495–1504.
14. Helske S. Syvaranta S. Lindstedt K.A. Lappalainen J. Oorni K. Mayranpaa M.I. et al. (2006 b) Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler Thromb Vasc Biol 26: 1791–1798.
15. Huh C. Nagle J.W. Kozak C.A. Abrahamson M. Karlsson S. (1995) Structural organization, expression and chromosomal mapping of the mouse cystatin-C-encoding gene (Cst3). Gene 152: 221–226.
16. Kaden J.J. Bickelhaupt S. Grobholz R. Haase K.K. (2004) Receptor activator of nuclear factor [kappa] B ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36: 57–66.
17. Kaden J.J. Dempfle C.E. Grobholz R. Fischer C.S. Vocke D.C. Kill R. et al. (2005) Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 14: 80–87.
18. Liu A.C. Joag V.R. Gotlieb A.I. (2007) The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 171: 1407–1418.
19. Mallat Z. Tedgui A. (2004) Unbalanced RANKL / RANK pathway in aortic valve sclerosis. J Mol Cell Cardiol 36: 17–19.
20. Mead T. Yutzev K. (2009) Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development. Proc Natl Acad Sci U S A 106: 14420–14425.
21. Meier-Stiegen F. Schwanbeck R. Bernoth K. Martini S. Hieronymus T. Ruau D. et al. (2010) Activated Notch 1 target genes during embryonic cell differentiation depend on the cellular context and include lineage determinants and inhibitors. PloS ONE 5: e11481.
22. Meng X. Ao L. Song Y. Babu A. Yang X. Wang M. et al. (2008) Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis. Am J Physiol Cell Physiol 294: C29–C35.
23. Miller J.D. Chu Y. Brooks R.M. Richenbacher W.E. Pena-Silva R. Heistad D.D. (2008) Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 52: 843–850.
24. Mohler E.R. III (2004) Mechanisms of aortic valve calcification. Am J Cardiol 94: 1396–1402.
25. Nordstrom P. Glader C.A. Dahlen G. Birgander L.S. Lorentzon R. Waldenstrom A. et al. (2003) Oestrogen receptor α gene polymorphism is related to aortic valve sclerosis in postmenopausal women. J Intern Med 254: 140–146.
26. Novaro G.M. Sachar R. Pearce G.L. Sprecher D.L. Griffin B.P. (2003) Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation 108: 1804–1808.
27. Ortlepp J.R. Hoffmann R. Ohme F. Lauscher J. Bleckmann F. Hanrath P. (2001) The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 85: 635–638.
28. Osman L. Yacoub M.H. Latif N. Amrani M. Chester A.H. (2006) Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 114: I-547–I-552.
29. Otto C.M. Kuusisto J. Reichenbach D.D. Gown A.M. O'Brien K.D. (1994) Characterization of the early lesion of degenerative valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90: 844–853.
30. Parolari A. Loardi C. Mussoni L. Cavallotti L. Camera M. Biglioli P. et al. (2009) Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention. Eur J Cardiothorac Surg 35: 493–504.
31. Parolari A. Tremoli E. Cavallotti L. Trezzi M. Kassem S. Loardi C. et al. (2011) Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis? Heart 97: 523–529.
32. Peacock J. Levay A. Gillaspie D. Tao G. Lincoln J. (2010) Reduced Sox 9 function promotes heart valve calcification phenotypes in vivo. Circ Res 106: 712–719.
33. Perrotta I. Russo E. Camastra C. Filice G. Mizio G. Colosimo F. et al. (2011) New evidence for a critical role of elastin in calcification of native heart valves: immunohistochemical and ultrastructural study with literature review. Histopathology 59: 504–513.
34. Rajamannan N.M. (2009) Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 29: 162–168.
35. Rajamannan N.M. (2010) Mechanisms of aortic valve calcification: the LDL-density-radius theory: a translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol 298: H5-H15.
36. Rajamannan N.M. (2011) The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory. J Cell Biochem 112: 2222–2229.
37. Rajamannan N.M. Subramaniam M. Caira F. Stock S.R. Spelsberg T.C. (2005) Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp 5 receptor pathway. Circulation 112: I-229–I-234.
38. Ramaraj R. Sorrell V.L. (2008) Clinical Review: Degenerative aortic stenosis. BMJ 336: 550–555.
39. Salas M. Santana O. Escolar E. Lamas G. (2011) Medical therapy for calcific aortic stenosis. J Cardiovasc Pharmacol Ther [ePub ahead of print].
40. Schoen F.J. (2005) Cardiac valves and valvular pathology: update on function, disease, repair, and replacement. Cardiovasc Pathol 14: 189–194.
41. Soini Y. Salo T. Satta J. (2003) Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum Pathol 34: 756–763.
42. Spargias K. Milewski K. Debinski M. Buszman P. Cokkinos D. Pogge R. et al. (2009) Drug delivery at the aortic valve tissues of healthy domestic pigs with a paclitaxel-eluting valvuloplasty balloon. J Intervent Cardiol 22: 291–298.
43. Sun Y.A.O. Ratajska A. Weber K.T. (1995) Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med 126: 95–101.
44. Taylor P.M. Batten P. Brand N.J. Thomas P.S. Yacoub M.H. (2003) The cardiac valve interstitial cell. Int J Biochem Cell Biol 35: 113–118.
45. Toutouzas K. Drakopoulou M. Synetos A. Tsiamis E. Agrogiannis G. Kavantzas N. et al. (2008) In vivo aortic valve thermal heterogeneity in patients with nonrheumatic aortic valve stenosis. The first in vivo experience in humans. J Am Coll Cardiol 52:758–763.
46. Wallner K. Li C. Shah P.K. Fishbein M.C. Forrester J.S. Kaul S. et al. (1999) Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 99: 1284–1289.
47. Waters E. Chen J. Allen J. Zhang H. Lanza G. Wickline S. (2008) Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson 10: 43.
48. Xu S. Liu A.C. Gotlieb A.I. (2010) Common pathogenic features of atherosclerosis and calcific aortic stenosis: role of transforming growth factor-[beta]. Cardiovasc Pathol 19: 236–247.
49. Yang X. Fullerton D.A. Su X. Ao L. Cleveland J.C. Jr Meng X. (2009) Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J Am Coll Cardiol 53: 491–500.
50. Yetkin E. Waltenberger J. (2009) Molecular and cellular mechanisms of aortic stenosis. Int J Cardiol 135: 4–13.